Ultragenyx Pharmaceutical Stock Discussion

» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...

$United Therapeutics (UTHR.US)$  Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$  Phase 3
$Liquidia (LQDA.US)$  Phase 3
$United Therapeutics (UTHR.US)$  Phase 3
$MorphoSys (MOR.US)$  Phase 3
$Immunocore (IMCR.US)$  Phase 3
$Crinetics (CRNX.US)$  Phase 3
$UroGen Pharma Ltd (URGN.US)$  Phase 3
$AstraZeneca (AZN.US)$  Phase 3
$AstraZeneca (AZN.US)$  Phase 3
$AstraZeneca (AZN.US)$  Phase 3
$AstraZeneca (AZN.US)$  Phase 3
$Capricor Therapeutics (CAPR.US)$  Phase 3
$Annexon (ANNX.US)$  Phase 3
$Lipocine (LPCN.US)$  Phase 3...

$Travere Therapeutic (TVTX.US)$  Phase 3
$CG Oncology (CGON.US)$  Phase 3
$United Therapeutics (UTHR.US)$  Phase 3
$United Therapeutics (UTHR.US)$  Phase 3
$BioCardia (BCDA.US)$  Phase 3
$Insmed (INSM.US)$  Phase 3
$GlycoMimetics (GLYC.US)$  Phase 3
$Annexon (ANNX.US)$  Phase 3
$Lipocine (LPCN.US)$  Phase 3
$FibroGen (FGEN.US)$  Phase 3
$UroGen Pharma Ltd (URGN.US)$  Phase 3
$Lyra Therapeutics (LYRA.US)$  Phase 3
$Citius Pharmaceuticals (CTXR.US)$  Phase 3
$Jaguar Health (JAGX.US)$  Phas...

🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies (ITCI.US)$  Phase 3
$CG Oncology (CGON.US)$  Phase 3
$Hutchmed (China) (HCM.US)$  Phase 3
$Viracta Therapeutics (VIRX.US)$  Phase 3
$GlycoMimetics (GLYC.US)$  Phase 3
$Annexon (ANNX.US)$  Phase 3
$Lipocine (LPCN.US)$  Phase 3
$FibroGen (FGEN.US)$  Phase 3
$UroGen Pharma Ltd (URGN.US)$  Phase 3
$Lyra Therapeutics (LYRA.US)$  Phase 3
$Citius Pharmaceuticals (CTXR.US)$  Phase 3
$Marinus Pharmaceuticals (MRNS.US)$  Phase 3
$BioCardia (BCDA.US)$  Phase 3...

Gainers:
In reaction to earnings/guidance:
• $Silvergate Capital (SI.US)$ +10.7% (Silvergate (ticker: SI) notched net income of $38.6 million in the June quarter, delivering earnings per share (EPS) of $1.13.)
• $AxoGen (AXGN.US)$ +3.3% (guides Q2 revs above consensus; also makes changes to its commercial organization),
• $Novartis AG (NVS.US)$ + 3% (The Swiss pharmaceutical company on Tuesday posted net profit of $1.69 billion, down from...